Share
.webp)
.webp)
.webp)
.webp)
Dr. Heather Preston
Monument Therapeutics, a precision-neuroscience company advancing innovative treatments for serious central nervous system (CNS) disorders, announced two key additions to its leadership team.
Robert S. Radie has been appointed Non-Executive Chair of the Board, and Dr. Heather Preston has joined the company’s Advisory Board.
Dr. Preston, a seasoned healthcare investor and physician, brings more than two decades of experience in venture capital and strategic advisory roles. She has held board positions at numerous life sciences companies and was previously on the Board of Karuna Therapeutics, a CNS-focused company acquired by Bristol Myers Squibb for US$14 billion in 2024. Dr. Preston has a long-standing interest in improving treatments for schizophrenia and other serious mental health conditions.
These appointments reflect Monument Therapeutics' ongoing commitment to strengthening its leadership and advisory capabilities as it advances its precision neuroscience pipeline.
